Drug intelligence / Profile preview

BOS172767 enantiomer E1 or E2

Development stage: Phase 1
Lead developer: Boston Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

BOS172767 enantiomer E1 or E2 refers to the two stereoisomers (enantiomers) of the small molecule drug candidate BOS172767. This compound is a RORγt (RAR-related orphan receptor gamma 2) inhibitor, developed as an oral agent. The mechanism of action involves inhibition of RORγt, a nuclear receptor that plays a key role in the differentiation and function of Th17 cells and is implicated in autoimmune diseases such as multiple sclerosis. Clinical development has included Phase 1 studies to determine the relative bioavailability and pharmacokinetics of each enantiomer[1][2].

Targets

RORγt

Beyond the preview

Go deeper on BOS172767 enantiomer E1 or E2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BOS172767 enantiomer E1 or E2.

Explore the full profile